P117 HbA1C monitoring in patients with cystic fibrosis related diabetes (CFRD) during Covid 19 Pandemic

P117 HbA1C monitoring in patients with cystic fibrosis related diabetes (CFRD) during Covid 19 Pandemic

IntroductionCystic fibrosis (CF) affects the pancreas, particularly the β-cells, leading to cystic fibrosis-related diabetes (CFRD) due to insulin deficiency. There is a lack of UK national guidance on how often HbA1C should be monitored. American Diabetes Association (ADA) recommends HbA1c should b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thorax 2021-11, Vol.76 (Suppl 2), p.A130-A130
Hauptverfasser: Zafran, M, Yousif, M, Bhaskaran, D, Robinson, J, Read, J, Keele, A, Bateman, K
Format: Artikel
Sprache:eng
Schlagworte:
COVID-19
Cystic fibrosis
Diabetes
Glucose
Hemoglobin
Pandemics
Thinking outside the lung: monitoring and management of patients with CF, PCD and bronchiectasis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:IntroductionCystic fibrosis (CF) affects the pancreas, particularly the β-cells, leading to cystic fibrosis-related diabetes (CFRD) due to insulin deficiency. There is a lack of UK national guidance on how often HbA1C should be monitored. American Diabetes Association (ADA) recommends HbA1c should be monitored quarterly for patients with CFRD.1 For most patients with CFRD, the HbA1C treatment goal is
ISSN:0040-6376
1468-3296
DOI:10.1136/thorax-2021-BTSabstracts.226